Henoch-Schönlein purpura.
OBJECTIVE
To provide an update on recent advances in the genetic susceptibility, pathogenesis and treatment of Henoch-Schönlein purpura.


RESULTS
Recent work has advanced our understanding of the genetic susceptibility and pathogenesis of Henoch-Schönlein purpura, but there are still significant gaps in our knowledge. Information concerning the most effective treatment of Henoch-Schönlein purpura has begun to emerge. Corticosteroid therapy reduces the duration and severity of abdominal and joint pain, but corticosteroids do not prevent the development of nephritis, or alter the natural history of Henoch-Schönlein purpura. The most effective treatment for severe nephritis remains unclear despite multiple, mostly retrospective reports investigating a variety of drugs.


CONCLUSIONS
Despite recent progress, our understanding of the genetic susceptibility, pathogenesis and treatment of Henoch-Schönlein purpura remains incomplete. Further research is necessary in order to clearly define the genetic susceptibility and the pathogenesis of Henoch-Schönlein purpura. Multicenter clinical trials are needed to determine the most effective treatment of Henoch-Schönlein purpura, particularly for patients with severe nephritis.
Saulsbury
Frank T
FT
Division of Immunology and Rheumatology, Department of Pediatrics, University of Virginia Health System, Charlottesville, Virginia, USA. fts@virginia.edu
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones